Impact of COVID-19 Infection on 24 Patients with Sickle Cell Disease. One Center Urban Experience, Detroit, MI, USA
Impact of COVID-19 Infection on 24 Patients with Sickle Cell Disease. One Center Urban Experience, Detroit, MI, USA
复制标题
DOI：
10.1080/03630269.2020.1797775
复制
发表时间：
2020-07-28
期刊：
影响因子：
1
通讯作者：
Dabak, Vrushali
中科院分区：
文献类型：
--
作者：
Balanchivadze, Nino;Kudirka, Adam A.;Dabak, Vrushali
底特律市有大量镰状细胞病患者，底特律的医院在2020年出现了最多的冠状病毒病-19 （COVID-19）病例。本研究的目的是研究COVID-19在镰状细胞病或特征患者中的病理生理特征，以确定这些患者是否具有可能需要特别考虑的独特表现。这项回顾性分析包括2020年3月1日至4月15日期间在美国密歇根州底特律亨利福特医院就诊的24例确诊的COVID-19和镰状细胞病或特征患者。在24例患者中，18例（75.0%）具有杂合子镰状细胞特征，1例（4.0%）为Hb S (HBB: C . 20a >T)/ β(+)-地中海贫血（β (+)-thal）双杂合子，4例患有镰状细胞贫血(β (S)/ β (S))， 1例（4.0%）患有Hb S/Hb C （HBB: C . 19g > a）疾病。13例（54.0%）患者需要住院治疗。4例镰状细胞性贫血患者均出现急性疼痛危象。我们观察到一名患者发生急性肺栓塞，没有患者发生其他镰状细胞相关并发症。此外，3例（13.0%）患者无需换血而需要填充红细胞输血，1例患者需要入住重症监护病房（ICU），进行机械通气，随后死亡。患有镰状细胞病或特征并经实验室确诊的COVID-19患者的病程通常较轻或不显著，插管、ICU住院和死亡的几率较低，但住院时间略长。
The city of Detroit has a large population of individuals with sickle cell disease, and hospitals in Detroit have seen some of the highest numbers of cases of coronavirus disease-19 (COVID-19) in 2020. The purpose of this study was to examine the pathophysiological characteristics of COVID-19 in patients with sickle cell disease or trait to determine whether these patients have unique manifestations that might require special consideration. This retrospective analysis included 24 patients with confirmed COVID-19 and sickle cell disease or trait who were seen at the Henry Ford Hospital, Detroit, MI, USA, between March 1 and April 15 2020. Of the 24 patients, 18 (75.0%) had heterozygous sickle cell trait, one (4.0%) was a double heterozygote for Hb S (HBB: c.20A>T)/beta(+)-thalassemia (beta(+)-thal), four had sickle cell anemia (beta(S)/beta(S)) and one (4.0%) had Hb S/Hb C (HBB: c.19G>A) disease. A total of 13 (54.0%) patients required hospitalization. All four patients with sickle cell anemia, developed acute pain crisis. We observed one patient who developed acute pulmonary embolism and no patients developed other sickle cell associated complications. Additionally, three (13.0%) patients required packed red blood cell transfusion without the need of exchange transfusion, and one patient required admission to the intensive care unit (ICU), mechanical ventilation and subsequently died. Patients with sickle cell disease or trait and laboratory-confirmed COVID-19 had a generally mild, or unremarkable, course of disease, with lower chances of intubation, ICU admission and death, but with a slightly longer hospitalization.